Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion type Assertion NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_head.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion description "[Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_provenance.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion evidence source_evidence_literature NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_provenance.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion SIO_000772 21726823 NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_provenance.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion wasDerivedFrom befree-20140225 NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_provenance.
- NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_assertion wasGeneratedBy ECO_0000203 NP230537.RACyZ5_bs7qRcQOz8KMxcxuuAxjfeWR5AJTT3-6xeBm8c130_provenance.